|
CNV status
|
N = 213
|
Genetic mutation of therapeutic targets
|
|---|
|
N (%)
|
% (No. positive cases/no. examined cases)
|
|---|
|
KIT
|
BRAF
|
NRAS
|
|---|
|
≥ 1 CNV
|
|
CDK4 gain
|
100 (47.0)
|
7.4 (7/95)
|
5.2 (5/96)
|
15.7 (11/70)
|
|
2.5–5 copies
|
76 (35.7)
|
5.6 (4/71)
|
5.6 (4/72)
|
19.6 (11/56)
|
|
5–10 copies
|
14 (6.6)
|
11.8 (2/14)
|
0 (0/14)
|
0 (0/10)
|
|
>10 copies
|
10 (4.7)
|
10.0 (1/10)
|
10.0 (1/10)
|
0 (0/4)
|
|
CCND1 gain
|
59 (27.7)
|
1.8 (1/56)
|
8.9 (5/56)
|
10.4 (5/48)
|
|
2.5–5 copies
|
49 (23.0)
|
0 (0/46)
|
10.9 (5/46)
|
112.8 (5/39)
|
|
5–10 copies
|
9 (4.2)
|
11.1 (1/9)
|
0 (0/9)
|
0 (0/8)
|
|
> 10 copies
|
1 (0.5)
|
0 (0/1)
|
0 (0/1)
|
0 (0/1)
|
|
P16INK4a loss
|
123 (57.7)
|
9.6 (11/114)
|
4.3 (5/115)
|
10.5 (9/86)
|
|
Overall
|
174 (81.7)
|
7.0 (11/199)
|
10.0 (10/200)
|
13.7 (21/153)
|
|
≥ 2 CNVs
|
|
CDK4 gain plusCCND1 gain
|
13 (6.1)
|
0 (0/12)
|
0 (0/12)
|
20.0 (2/10)
|
|
CDK4 gain plus P16INK4aloss
|
49 (23.0)
|
12.8 (6/47)
|
4.2 (2/48)
|
12.1 (4/33)
|
|
CCND1 gain plus P16INK4aloss
|
16 (7.5)
|
6.3 (1/16)
|
0 (0/16)
|
15.4 (2/13)
|
|
Overall
|
78 (36.6)
|
9.3 (7/75)
|
3.9 (3/76)
|
14.3 (8/56)
|
|
3 CNVs
|
|
Overall
|
17 (8.0)
|
0 (0/16)
|
12.5 (2/16)
|
0 (0/14)
|
- CNV copy number variation
